The global bladder cancer therapeutics & diagnostic market is segmented based on:
Transitional cell bladder cancer
Invasive bladder cancer
Superficial bladder cancer
Squamous cell bladder cancer
Other rare types
North America, followed by Europe, holds the largest market for bladder cancer treatment drugs due to the availability of better health care solutions and rise in bladder cancer cases in the region. Asia is expected to experience a high growth in the bladder cancer treatment drugs market in the coming years due to the developing health care infrastructure in the region.
Some of the key participants in the industry include Pfizer, GlaxoSmithKline, Sanofi S.A, Roche, Novartis, Eli Lilly and Co, AstraZeneca plc, Bristol-Myers Squibb etc.
Increasing bladder cancer cases
Drug innovations with regard to the bladder cancer
Rise in aging populace
Advanced health care services
Upsurge in awareness about bladder diseases and their available therapies in the market
Increasing health care expenditure
Rise in the number of patent expirations
Rise in the use of generic drugs
Asymptomatic nature of the disease
SPECIALITIES OF THIS REPORT
The report will be useful in gaining an exhaustive understanding of the regional market. It will also be of assistance in providing a comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.
The report will be an ideal source material for industry consultants, manufacturers and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.
The report contains wide range of information about the leading market players and the major strategies adopted by them.
WHAT THE REPORT OFFERS
Market definition along with identification of key drivers and restraints for the market.
Market analysis with region specific assessments and competition analysis on a global and regional scale.
Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares.
Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
1.1 Market Definition
1.2 Research Methodology
1.3 Markets Covered
2. Executive Summary
3. Market Overview
3.1 Market Drivers
3.1.1 Rise in awareness about bladder diseases and their available therapies
3.1.2 Increasing health care expenditure
3.1.3 Innovation in drug development, and subsequent technological advancements
3.2 Market Restraints
3.2.1 Rise in number of patent expirations
3.2.2 Increase in use of generic drugs
3.2.3 Asymptomatic nature of the disease
3.3 Market Opportunitites
3.4 Market Threats
4. Porters Five Force Analysis
4.1 Bargaining Power of suppliers
4.2 Bargaining power of buyers
4.3 Degree of competition
4.4 Threat of substitution
4.5 Threat of new entrants
5. Market Segmentation
5.1 Global Bladder Cancer Therapeutics & Diagnostics Market, by Cancer Type
5.1.1 Transitional Cell Bladder Cancer
5.1.2 Superficial Bladder Cancer
5.1.3 Invasive bladder cancer
5.1.4 Squamous cell bladder cancer
5.1.5 Other rare types
5.2 Global Bladder Cancer Therapeutics Market
5.2.3 Radiation therapy
5.3 Global Bladder Cancer Diagnostics Market
5.3.4 Urine Cytology
5.3.5 Bladder Ultrasound
5.4 Global Bladder Cancer Therapeutics & Diagnostics Market, By Region
5.4.1 North America
184.108.40.206 Rest Of Europe
5.4.4 Latin America
5.4.5 Middle East & Africa
6. Competitive Landscape
6.1 Mergers & Acquisitions
6.2 Agreements, Collaborations & Partnerships
6.3 New Product Launches
6.4 Recommendations to new market players
7. Company Profiles
7.1 Novartis International AG
7.2 Pfizer Inc
7.3 GlaxoSmithKline plc
7.4 Sanofi S.A
7.5 Eli Lilly and Co
7.6 AstraZeneca plc
7.7 Bristol-Myers Squibb
7.8 F. Hoffmann-La Roche AG
7.9 Celgene Corporation